Abstracts

MODELING-SUPPORTED ISLATRAVIR DOSE SELECTION FOR PHASE III

Islatravir (ISL) is the first nucleoside reverse transcriptase translocation inhibitor (NRTTI) in development for the treatment and prevention of HIV-1 infection. Single doses of ISL as low as 0.5 mg showed robust efficacy in a proof-of-concept (POC) clinical trial and established an IQ (ratio of drug exposure to potency) of 5 for ISL for wild-type…

MK-8504 AND MK-8583 (TENOFOVIR PRODRUGS) SINGLE-DOSE PK AND ANTIVIRAL ACTIVITY IN HIV

There is a need for Human Immunodeficiency Virus (HIV-1) treatments with improved safety profiles and increased ease of administration. MK-8504 and MK-8583 are nucleoside reverse transcriptase inhibitors (NRTIs) that are novel tenofovir (TFV) prodrugs, with a potential for weekly dosing due to the long t1/2 of the active diphosphate (TFV-DP). Single-dose pharmacokinetics (PK) and antivirologic…

BICTEGRAVIR DISTRIBUTION AND BICTEGRAVIR/FTC/TAF ACTIVITY IN GENITAL TRACT AND RECTUM

Antiretroviral distribution in the genital tract (GT) and rectum is required to suppress HIV replication within these compartments. Pharmacokinetics and HIV decay in the GT and rectum have not yet been described for the new integrase inhibitor bictegravir (BIC).  Prospective study of HIV-1–infected, ART–naive males (n=15) and females (n=8) initiating BIC/F/TAF 50/200/25 mg. HIV-1 RNA was…

CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION

Long-acting (LA) regimens of cabotegravir (CAB) + rilpivirine (RPV) given monthly and every 2-months are in development for maintenance of HIV suppression. Both products exhibit absorption-rate limited PK following intramuscular (IM) administration, with apparent half-life (t1/2) estimates of 5.6 -11 weeks (CAB) and 28 weeks (RPV). Following LA treatment discontinuation, CAB and RPV may remain…

ARV PENETRATION INTO FEMALE GENITAL TRACT DURING PREGNANCY: EFAVIRENZ AS A CASE STUDY

Proper characterisation of antiretroviral pharmacokinetics in the female genital tract is crucial in developing effective pre-exposure prophylaxis and prevention of intrapartum mother-to-child transmission interventions. Progress in this area has been limited by sampling constraints. A novel assay to quantify efavirenz in cervicovaginal fluid from flocked swabs using LC-MS/MS was developed and validated as per FDA…